TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37844519

Group type: EXPERIMENTAL
Intervention: Cerebral Blood Flow (CBF) measurement using jugular venous flow
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Aortic-Pulmonary Collateral (APC) flow measurement
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Brain Injury (BI) assessment (focal BI, generalized insult, and hemorrhage)
Number of subjects: 27
Study: 37844597

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg IV every 2 weeks)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg and 1 mg/kg respectively) boosts
Number of subjects: 207

Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab
Number of subjects: 207
Study: 37844598

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenous once every 3 weeks plus lenvatinib 20 mg oral once per day for up to 2 years or until disease progression, development of unacceptable toxicity, or withdrawal of consent.
Number of subjects: 38
Study: 37844796

Group type: EXPERIMENTAL
Intervention: High-pressure mechanical insufflation-exsufflation (HP-MIE)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-pressure mechanical insufflation-exsufflation (LP-MIE)
Number of subjects: 29
Study: 37844838

Group type: COMPARATOR
Intervention: 36 h fasting
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous glucose administration
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral lactate administration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous lactate administration
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Oral Na-β-hydroxybutyrate (BHB) administration
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intravenous Na-β-hydroxybutyrate (BHB) administration
Number of subjects: 74
Study: 37844986

Group type: EXPERIMENTAL
Intervention: OCA group (oxycodone: 0.5 mg/kg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: OCB group (oxycodone: 1.0 mg/kg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: OCC group (oxycodone: 1.5 mg/kg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Sufentanil group (sufentanil: 2 µg/kg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups (including flurbiprofen 50 mg and ondansetron 16 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study: 37844988

Group type: EXPERIMENTAL
Intervention: Online screening of HIV and STIs with self-sampling kits; participants alternate face-to-face meetings with online screening.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual follow-up protocol with quarterly face-to-face visits for HIV and STI testing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptability of the intervention among participants and healthcare workers.
Number of subjects: 0
Study: 37845108

Group type: EXPERIMENTAL
Intervention: In-cabin tracheal intubation
Number of subjects: 422

Group type: COMPARATOR
Intervention: Outside cabin tracheal intubation
Number of subjects: 422
Study: 37845427

Group type: EXPERIMENTAL
Intervention: Idarucizumab (2×2.5 g/50 ml) in group A
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Idarucizumab (2×2.5 g/50 ml) in group B
Number of subjects: 804
Study: 37845502

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) glasses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Audio (vocal-guided affective imagery)
Number of subjects: 40
Study: 37845511

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg every 4 weeks for 12 months
Number of subjects: 790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Nivolumab 480 mg
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 790
Study: 37845512

Group type: EXPERIMENTAL
Intervention: 100 mg resmetirom
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: 80 mg resmetirom
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Open-label 100 mg resmetirom
Number of subjects: 1143
Study: 37845588

Group type: EXPERIMENTAL
Intervention: CHW telehealth intervention (5 virtual group-based health education sessions, an action plan, and follow-up calls)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (only the first session)
Number of subjects: 190
Study: 37845603

Group type: EXPERIMENTAL
Intervention: Simultaneous cognitive-exercise training (SCET)
Number of subjects: 106
Study: 37845604

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) angioplasty
Number of subjects: 84

Group type: COMPARATOR
Intervention: Plain old balloon (POB) dilatation
Number of subjects: 84
Study: 37845608

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E subunit herpes zoster vaccine (RZV)
Number of subjects: 875
Study: 37845612

Group type: EXPERIMENTAL
Intervention: Oropharyngeal administration of 0.2 ml colostrum every 3 hours for 5 consecutive days.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Oropharyngeal administration of sterile water (control group).
Number of subjects: 320
Study: 37845624

Group type: EXPERIMENTAL
Intervention: All-cause in-hospital mortality
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Admission to intensive care unit
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Duration of hospitalisation
Number of subjects: 35000

Group type: EXPERIMENTAL
Intervention: Level of respiratory support required
Number of subjects: 35000
Study: 37845696

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (NI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy (pemetrexed plus cisplatin/carboplatin, C)
Number of subjects: 0
Study: 37845752

Group type: EXPERIMENTAL
Intervention: Telehealth gait retraining intervention with standard of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 37845776

Group type: EXPERIMENTAL
Intervention: G-NoMAD questionnaire (German version)
Number of subjects: 539
Study: 37846080

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 392

Group type: COMPARATOR
Intervention: Investigator-chosen chemotherapy (paclitaxel, docetaxel, or irinotecan)
Number of subjects: 392
Study: 37846437

Group type: EXPERIMENTAL
Intervention: RENEW intervention (12-week resilience-building energy management program including an educational website/application and nine virtual peer-led health coaching sessions)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: RENEW intervention
Number of subjects: 173

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 173
Study: 37846456

Group type: EXPERIMENTAL
Intervention: 15-valent V114 (PCV15)
Number of subjects: 2

Group type: COMPARATOR
Intervention: 20-valent PCV20
Number of subjects: 2
Study: 37846462

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 and 1.0 mg/kg)
Number of subjects: 31
Study: 37846607

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ASV 1508 and ASV 664
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Gut microbiota composition
Number of subjects: 93
Study: 37846664

Group type: EXPERIMENTAL
Intervention: COVID-19 severity measured on a five-level ordinal scale
Number of subjects: 1383
Study: 37846724

Group type: EXPERIMENTAL
Intervention: TAK-003 (Qdenga®), a live attenuated dengue tetravalent vaccine, administered during the second half of its 24-month shelf-life
Number of subjects: 0
Study: 37846737

Group type: EXPERIMENTAL
Intervention: Non-refugee immigrants with psychotic disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native-born individuals with psychotic disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-refugee immigrants with psychosis
Number of subjects: 0
Study: 37846769

Group type: EXPERIMENTAL
Intervention: POLARx cryoballoon system
Number of subjects: 125
Study: 37846845

Group type: EXPERIMENTAL
Intervention: Early relapse within 18 months (ER18) after initial treatment
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Early relapse within 18 months (ER18)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Dynamic risk assessment
Number of subjects: 629
Study: 37846935

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Oxygen (HFNO) treatment
Number of subjects: 696

Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (IMV)
Number of subjects: 696
Study: 37847068

Group type: EXPERIMENTAL
Intervention: EXP (mentally fatiguing task; individualized 60-min Stroop task)
Number of subjects: 14

Group type: COMPARATOR
Intervention: CON (control task; documentary)
Number of subjects: 14
Study: 37847109

Group type: EXPERIMENTAL
Intervention: FLACS diabetic
Number of subjects: 152

Group type: COMPARATOR
Intervention: MCS diabetic
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: FLACS
Number of subjects: 152
Study: 37847127

Group type: EXPERIMENTAL
Intervention: Premium monovision (Panoptix IOL in recessive eye and Vivity IOL in dominant eye)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bilateral trifocal (Panoptix IOL bilaterally)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bilateral xEDOF (Vivity IOL bilaterally)
Number of subjects: 90
Study: 37847131

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT)
Number of subjects: 1408

Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) without intravenous thrombolysis (IVT)
Number of subjects: 1408
Study: 37847138

Group type: EXPERIMENTAL
Intervention: 2D CE US 4-6 weeks after TACE
Number of subjects: 132

Group type: COMPARATOR
Intervention: CE MRI or CT 4-6 weeks after TACE
Number of subjects: 132
Study: 37847273

Group type: EXPERIMENTAL
Intervention: Million Hearts Model intervention
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 342

Group type: COMPARATOR
Intervention: Medicare spending for CVD events
Number of subjects: 342

Group type: COMPARATOR
Intervention: Overall Medicare spending including model payments
Number of subjects: 342
Study: 37847288

Group type: EXPERIMENTAL
Intervention: Hemp supplementation (60 g/d containing 40 g protein and 9 g oil)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Soy supplementation (60 g/d matched for protein and calories)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hemp supplementation
Number of subjects: 34
Study: 37847317

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g of omega-3 acid ethyl esters, Lovaza)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 60
Study: 37847423

Group type: EXPERIMENTAL
Intervention: Involvement of pharmacists in deprescribing interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deprescribing interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emotional barriers identified by clinicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional facilitators identified by pharmacists
Number of subjects: 0
Study: 37847442

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4385

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4385
Study: 37847454

Group type: EXPERIMENTAL
Intervention: Helmet-CPAP
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-rebreather mask (NRB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oxygen masks with higher FiO
Number of subjects: 28
Study: 37847518

Group type: EXPERIMENTAL
Intervention: 100-µg mRNA-1273 (Moderna)
Number of subjects: 273

Group type: COMPARATOR
Intervention: 30-µg BNT162b2 (Pfizer-BioNTech)
Number of subjects: 273
Study: 37847542

Group type: EXPERIMENTAL
Intervention: Virtual Reality Meditation (VRM)
Number of subjects: 13
Study: 37847548

Group type: EXPERIMENTAL
Intervention: Telepsychiatry (n=240)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Historical controls (face-to-face evaluation, n=240)
Number of subjects: 480
Study: 37847688

Group type: EXPERIMENTAL
Intervention: nintedanib 150 mg BID plus weekly docetaxel (35 mg/m2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: nintedanib 200 mg BID plus weekly docetaxel (35 mg/m2)
Number of subjects: 14
Study: 37847695

Group type: EXPERIMENTAL
Intervention: Medication Review with Follow-up (MRF) service
Number of subjects: 162
Study: 37847761

Group type: EXPERIMENTAL
Intervention: Epirubicin (mean dose of 304 mg/m²)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls (sex- and age-matched)
Number of subjects: 25
Study: 37847768

Group type: EXPERIMENTAL
Intervention: FlowTriever mechanical thrombectomy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Other contemporary therapies (primarily systemic thrombolysis and anticoagulation)
Number of subjects: 114
Study: 37847947

Group type: COMPARATOR
Intervention: High-intensity percutaneous electrolysis (three pulses of 3 mA, 3s)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Low-intensity percutaneous electrolysis (0.3 mA, 90s)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sham (without electrical current)
Number of subjects: 46
Study: 37848174

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1107

Group type: EXPERIMENTAL
Intervention: Edoxaban (pre-TAVR VKA users)
Number of subjects: 1107

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 1107
Study: 37848259

Group type: EXPERIMENTAL
Intervention: Cosibelimab 800 mg intravenously every 2 weeks
Number of subjects: 78
Study: 37848292

Group type: EXPERIMENTAL
Intervention: Digital emergency manual (EM) used by resuscitation teams after a management plan has been derived ('Do-Confirm').
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Team's subjective evaluation of the EM's value on a Likert scale of 1-6.
Number of subjects: 50
Study: 37848295

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) and clinical examinations at 0, 3, 6, and 12 months
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Neurocognitive evaluation, 6-minute walk test (6MWT), and hand grip strength measurement at baseline
Number of subjects: 500
Study: 37848297

Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 5 mg/kg orally for 3 days prior to surgery.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 10 mg/kg orally for 3 days prior to surgery (if tolerated).
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 20 mg/kg orally for 3 days prior to surgery (if tolerated).
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP)
Number of subjects: 3
Study: 37848299

Group type: EXPERIMENTAL
Intervention: Parent-child yoga intervention in addition to standard clinical care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard clinical care alone
Number of subjects: 24
Study: 37848307

Group type: EXPERIMENTAL
Intervention: Upgraded 6-month intensive cardiac rehabilitation programme combining nutritional counselling, Mediterranean diet, and exercise training.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 8:16 hour time-restricting eating (TRE) at least 5 days per week added to the existing interventions in Phase 2.
Number of subjects: 36
Study: 37848336

Group type: EXPERIMENTAL
Intervention: Dry electrode EEG (8 electrodes) performed by ambulance personnel
Number of subjects: 311
Study: 37848634

Group type: EXPERIMENTAL
Intervention: CS1-BCMA CAR-T infusion
Number of subjects: 16
Study: 37848651

Group type: EXPERIMENTAL
Intervention: Elevated baseline levels of high-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: hs-CRP levels
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed with CES-D
Number of subjects: 585
Study: 37848690

Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention (home-based program)
Number of subjects: 133
Study: 37848768

Group type: EXPERIMENTAL
Intervention: simethicone (S)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: simethicone and N-acetyl cysteine (S + NAC)
Number of subjects: 800

Group type: COMPARATOR
Intervention: water (Control)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Late endoscopy (> 20-30 minutes)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Early endoscopy (10-20 minutes)
Number of subjects: 800
Study: 37848857

Group type: EXPERIMENTAL
Intervention: 15 min of mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 30 min of mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90
Study: 37848867

Group type: EXPERIMENTAL
Intervention: Long-term antiretroviral therapy (ART)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedural roadmap for study design
Number of subjects: 0
Study: 37848887

Group type: EXPERIMENTAL
Intervention: 20 mg immediate release methylphenidate (IR-MPH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37848908

Group type: EXPERIMENTAL
Intervention: MyoCare ophthalmic lenses
Number of subjects: 300

Group type: COMPARATOR
Intervention: Clearview ophthalmic lenses
Number of subjects: 300
Study: 37848916

Group type: EXPERIMENTAL
Intervention: ARCHES intervention
Number of subjects: 0
Study: 37848929

Group type: EXPERIMENTAL
Intervention: Drivingly Program (comprehensive parent-teen intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual practice control group
Number of subjects: 100
Study: 37848969

Group type: EXPERIMENTAL
Intervention: Home-based cluster-set resistance training program, 8 weeks, 3 days per week, with supervised sessions and virtual supervision
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Home-based cluster-set resistance training program
Number of subjects: 14
Study: 37848970

Group type: EXPERIMENTAL
Intervention: Interim methadone without routine counseling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Telehealth for counseling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remote counseling access
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intake through telehealth
Number of subjects: 16
Study: 37849000

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) targeting the cymba conchae of the external left ear, 5 min duration once daily for 2 weeks, followed by crossover to sham stimulation for 2 weeks, then ta-VNS 5 min duration twice daily until week 16.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) in UC subjects
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) in CD subjects
Number of subjects: 22
Study: 37849504

Group type: EXPERIMENTAL
Intervention: Clindamycin as adjunctive therapy
Number of subjects: 247
Study: 37849628

Group type: EXPERIMENTAL
Intervention: Zagotenemab 70 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Zagotenemab 210 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Zagotenemab (both doses)
Number of subjects: 22
Study: 37849833

Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation-induced cortical prehabilitation (NICP) protocol, involving 10 to 20 daily sessions of neuromodulation coupled with intensive task training.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-invasive NICP protocol
Number of subjects: 0
Study: 37850041

Group type: EXPERIMENTAL
Intervention: VIBe scale (Validated Intraoperative Bleeding Scale)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: VIBe scale
Number of subjects: 259
Study: 37850105

Group type: EXPERIMENTAL
Intervention: Wearable biosensor monitoring
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Generalized temporal models
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) and Mixed-Effect Random Forest (MERF) models
Number of subjects: 9
Study: 37850197

Group type: EXPERIMENTAL
Intervention: App-delivered cognitive-behavioral therapy for insomnia (CBT-I) adjunct to inpatient multimodal rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient multimodal rehabilitation (usual care)
Number of subjects: 0
Study: 37850330

Group type: EXPERIMENTAL
Intervention: Lidocaine and ketamine infusions
Number of subjects: 319
Study: 37850359

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 1773

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1773
Study: 37850379

Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg (equivalent to 284 mg of inclisiran)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 37850383

Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading with transseptal left atrial cannulation within 12 hours after randomization (n=58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional approach permitting rescue transseptal left atrial cannulation (n=58)
Number of subjects: 116
Study: 37850681

Group type: EXPERIMENTAL
Intervention: Anti-seizure medications
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Video-EEG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Follow-up EEG
Number of subjects: 20
Study: 37850816

Group type: EXPERIMENTAL
Intervention: HIVST
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: HIVST + mHealth
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 450
Study: 37850922

Group type: EXPERIMENTAL
Intervention: Livestock feed and nutritional counseling
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Livestock feed only
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1734
Study: 37850941

Group type: EXPERIMENTAL
Intervention: Tubeless Automated Insulin Delivery System
Number of subjects: 0
Study: 37851072

Group type: EXPERIMENTAL
Intervention: Rituximab/utomilumab/avelumab (cohort 1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rituximab/ivuxolimab/utomilumab (cohort 2)
Number of subjects: 24
Study: 37851095

Group type: EXPERIMENTAL
Intervention: Sodium-hyaluronate mouthwash
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 32
Study: 37851128

Group type: EXPERIMENTAL
Intervention: Serum Sirtuin6
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Saliva Lipoxin A4
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clinical periodontal parameters
Number of subjects: 40